Reduction of platelet trapping in membrane oxygenators by transmembraneous application of gaseous nitric oxide.
Bleeding during extracorporeal circulation (ECC) is often induced and/or aggravated by thrombocytopenia due to platelet-trapping in hollow fiber membrane oxygenators (HFMO). Nitric oxide (NO) has platelet anti-aggregating and dis-aggregating properties. In a paired system we tested whether gaseous NO, added to the gas compartment of one of two parallel running heparin-bonded HFMO attenuated platelet-trapping. Platelet consumption was markedly reduced in the NO-treated HFMO. These data strongly indicate that the application of gaseous NO could prove a new therapeutical approach to reduce bleeding during ECC, serving as a new way of preventing platelet loss, thus reducing the need for high systemic heparinization.
Keh
D
D
Dept. of Anaesthesiology and Intensive Care Medicine, Virchow Clinic, Humboldt University, Berlin, Germany.
Gerlach
M
M
Kürer
I
I
Falke
K J
KJ
Gerlach
H
H
D001672:Biocompatible Materials; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects; D005112:Extracorporeal Circulation; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009569:Nitric Oxide / Q000494:pharmacology / Q000627:therapeutic use*; D010107:Oxygenators, Membrane / Q000009:adverse effects*; D010313:Partial Pressure; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
D001672:Biocompatible Materials; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide; D006493:Heparin